Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations
{{output}}
Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) region showing some of the highest prevalence rates, reaching up to ... ...
